Study S002109

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Proof-of-Concept Study to Investigate Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over (STRIDES)

ClinicalTrials.gov record

Registration

Registration: NCT06515418
Acronym: STRIDES
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: TERMINATED
Enrollment: 204
Start: 2024-06-27
Primary completion: 2025-02-06
Lead sponsor: BioAge Labs, Inc.
Conditions: Obesity
Interventions: DRUG:Oral Azelaprag (BGE-105); DRUG:Oral Placebo for Azelaprag (BGE-105); DRUG:Tirzepatide; DRUG:Tirzepatide Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Mean Percent Change in Body Weight (Azelaprag Once per Day) [Week 24]
Mean Percent Change in Body Weight (Azelaprag Twice per Day) [Week 24]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.